Effects of early aminophylline therapy on clinical outcomes in premature infants

Open AccessPublished:November 23, 2022DOI:
      This paper is only available as a PDF. To read, Please Download here.



      Aminophylline use and the association between clinical outcomes and therapy timing have been less investigated. The objective of this study was to determine the efficacy of early aminophylline use (within the first two days of life) in premature infants.


      A retrospective observational cohort of infants weighing <1500 g and <30 weeks of gestational age at Kaohsiung Veterans General Hospital received aminophylline either within the first two days of life (EA, early aminophylline group), after the third day of life (LA, late aminophylline group), or without aminophylline during the first month of life (WA, without aminophylline group). Demographic data and neonatal clinical outcomes were compared among the three groups.


      This study included 89 preterm infants (EA = 33, LA = 38, WA = 18). The EA group had a lower incidence of bronchopulmonary dysplasia (BPD) than the WA group (adjusted odds ratio [aOR] =8.86(1.56-59.32); P=0.024). Although there was no significant difference in BPD incidence between the EA and LA groups (aOR=2.66(0.51-13.81), P=0.244), a trend remained. Birth body weight less than 1000 g was also a significant risk factor for BPD (aOR=8.86(1.32–47.41), P=0.014). The duration of mechanical ventilation was shorter in the infants in the EA group compared to the WA group (estimated beta = -11.344(-19.57–-3.12); P=0.008).


      Early aminophylline administration may be associated with a decreased incidence of BPD in preterm infants. However, the clinical benefits of aminophylline treatment require further investigation. In addition, a birth body weight of less than 1000 g was a crucial risk factor for BPD.